BriaCell Therapeutics Corp. (BCTX) has a negative trailing P/E of -0.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -339.14%.
Criteria proven by this page:
Overall SharesGrow Score: 50/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -86.1 | 2.17 | 244.07 | 0.00 | - |
| 2017 | -53.8 | 62.66 | 230.54 | 0.00 | - |
| 2018 | -31.1 | -0.93 | 178.23 | 0.00 | - |
| 2019 | -18.9 | 1.16 | -159.88 | 0.00 | - |
| 2020 | -13.9 | 0.45 | -19.14 | 0.00 | - |
| 2021 | -13.0 | 0.30 | 6.64 | 0.00 | - |
| 2022 | -29.1 | 0.67 | 74.98 | 0.00 | - |
| 2023 | -38.3 | 1.85 | -207.15 | 0.00 | - |
| 2024 | -18.9 | 0.24 | -37.44 | 0.00 | - |
| 2025 | -0.4 | -0.01 | 0.57 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-5.88 | $0.00 | $-1.7M | - |
| 2017 | $-7.32 | $0.00 | $-2.58M | - |
| 2018 | $2.49 | $0.00 | $1.07M | - |
| 2019 | $1.04 | $0.00 | $602.68K | - |
| 2020 | $-5.64 | $0.00 | $1.38M | - |
| 2021 | $-0.19 | $0.00 | $-2.89M | - |
| 2022 | $-1.73 | $0.00 | $-11.58M | - |
| 2023 | $-1.30 | $0.00 | $-20.3M | - |
| 2024 | $-0.29 | $0.00 | $-4.72M | - |
| 2025 | $-86.25 | $0.00 | $-36.5M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-11.45 | $-11.45 – $-11.45 | $2.1M | $2.1M – $2.1M | 1 |
| 2027 | $-3.40 | $-3.40 – $-3.40 | $10.1M | $10.1M – $10.1M | 1 |
